Logo do repositório

Percorrer por autor "Pfaar, O"

A mostrar 1 - 10 de 13
  • Allergen Immunotherapy in MASK‐Air Users in Real‐Life: Results of a Bayesian Mixed‐Effects Model
    Publication . Sousa‐Pinto, B; Azevedo, LF; Sá‐Sousa, A; Vieira, RJ; Amaral, R; Klimek, L; Czarlewski, W; Anto, JM; Bedbrook, A; Kvedariene, V; Ventura, MT; Ansotegui, IJ; Bergmann, KC; Brussino, L; Canonica, GW; Cardona, V; Carreiro‐Martins, P; Casale, T; Cecchi, L; Chivato, T; Chu, DK; Cingi, C; Costa, EM; Cruz, AA; De Feo, G; Devillier, P; Fokkens, WJ; Gaga, M; Gemicioğlu, B; Haahtela, T; Ivancevich, JC; Ispayeva, Z; Jutel, M; Kuna, P; Kaidashev, I; Kraxner, H; Larenas‐Linnemann, DE; Laune, D; Lipworth, B; Louis, R; Makris, M; Monti, R; Morais‐Almeida, M; Mösges, R; Mullol, J; Odemyr, M; Okamoto, Y; Papadopoulos, NG; Patella, V; Pham‐Thi, N; Regateiro, FS; Reitsma, S; Rouadi, PW; Samolinski, B; Sova, M; Todo‐Bom, A; Taborda‐Barata, L; Tomazic, PV; Toppila‐Salmi, S; Sastre, J; Tsiligianni, I; Valiulis, A; Wallace, D; Waserman, S; Yorgancioglu, A; Zidarn, M; Zuberbier, T; Fonseca, JA; Bousquet, J; Pfaar, O
    Background: Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. Objective: To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods: We assessed the MASK-air® data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales-VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season. Results: We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = -12.1;-2.8), lower VAS Work (average difference = 5.0; 95%CrI = -8.5;-1.5), and a lower CSMS (average difference = 3.7; 95%CrI = -9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = -17.2;-2.8), lower VAS Work (average difference = 7.8; 95%CrI = -15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = -18.5;0.2). Conclusion: In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its 'real-world' effectiveness.
    2022Artigo científico Acesso aberto Ver mais
  • ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
    Publication . Bousquet, J; Hellings, PW; Agache, I; Bedbrook, A; Bachert, C; Bergmann, KC; Bewick, M; Bindslev-Jensen, C; Bosnic-Anticevitch, S; Bucca, C; Caimmi, DP; Camargos, PAM; Canonica, G W; Casale, T; Chavannes, NH; Cruz, AA; De Carlo, G; Dahl, R; Demoly, P; Devillier, P; Fonseca, J; Fokkens, WJ; Guldemond, NA; Haahtela, T; Illario, M; Just, J; Keil, T; Klimek, L; Kuna, P; Larenas-Linnemann, D; Morais-Almeida, M; Mullol, J; Murray, R; Naclerio, R; O'Hehir, RE; Papadopoulos, NG; Pawankar, R; Potter, P; Ryan, D; Samolinski, B; Schunemann, HJ; Sheikh, A; Simons, FER; Stellato, C; Todo-Bom, A; Tomazic, PV; Valiulis, A; Valovirta, E; Ventura, MT; Wickman, M; Young, I; Yorgancioglu, A; Zuberbier, T; Aberer, W; Akdis, CA; Akdis, M; Annesi-Maesano, I; Ankri, J; Ansotegui, IJ; Anto, JM; Arnavielhe, S; Asarnoj, A; Arshad, H; Avolio, F; Baiardini, I; Barbara, C; Barbagallo, M; Bateman, D; Beghé, B; Bel, EH; Bennoor, KS; Benson, M; Białoszewski, AZ; Bieber, T; Bjermer, L; Blain, H; Blasi, F; Boner, L; Bonini, M; Bonini, S; Bosse, I; Bouchard, J; Boulet, LP; Bourret, R; Bousquet, PJ; Braido, F; Briggs, AH; Brightling, CE; Brozek, J; Buhl, R; Bunu, C; Burte, E; Bush, A; Caballero-Fonseca, F; Calderon, MA; Camuzat, T; Cardona, V; Carreiro-Martins, P; Carriazo, AM; Carlsen, K H; Carr, W; Cepeda Sarabia, AM; Cesari, M; Chatzi, L; Chiron, R; Chivato, T; Chkhartishvili, E; Chuchalin, AG; Chung, KF; Ciprandi, G; Correia de Sousa, J; Cox, L; Crooks, G; Custovic, A; Dahlen, SE; Darsow, U; Dedeu, T; Deleanu, D; Denburg, JA; De Vries, G; Didier, A; Dinh-Xuan, AT; Dokic, D; Douagui, H; Dray, G; Dubakiene, R; Durham, SR; Du Toit, G; Dykewicz, MS; Eklund, P; El-Gamal, Y; Ellers, E; Emuzyte, R; Farrell, J; Fink Wagner, A; Fiocchi, A; Fletcher, M; Forastiere, F; Gaga, M; Gamkrelidze, A; Gemicioğlu, B; Gereda, J E; van Wick, RG; González Diaz, S; Grisle, I; Grouse, L; Gutter, Z; Guzmán, MA; Hellquist-Dahl, B; Heinrich, J; Horak, F; Hourihane, JOB; Humbert, M; Hyland, M; Iaccarino, G; Jares, EJ; Jeandel, C; Johnston, SL; Joos, G; Jonquet, O; Jung, KS; Jutel, M; Kaidashev, I; Khaitov, M; Kalayci, O; Kalyoncu, A F; Kardas, P; Keith, PK; Kerkhof, M; Kerstjens, HAM; Khaltaev, N; Kogevinas, M; Kolek, V; Koppelman, GH; Kowalski, ML; Kuitunen, M; Kull, I; Kvedariene, V; Lambrecht, B; Lau, S; Laune, D; Le, LTT; Lieberman, P; Lipworth, B; Li, J; Lodrup Carlsen, KC; Louis, R; Lupinek, C; MacNee, W; Magar, Y; Magnan, A; Mahboub, B; Maier, D; Majer, I; Malva, J; Manning, P; De Manuel Keenoy, E; Marshall, GD; Masjedi, MR; Mathieu-Dupas, E; Maurer, M; Mavale-Manuel, S; Melén, E; Melo-Gomes, E; Meltzer, EO; Mercier, J; Merk, H; Miculinic, N; Mihaltan, F; Milenkovic, B; Millot-Keurinck, J; Mohammad, Y; Momas, I; Mösges, R; Muraro, A; Namazova-Baranova, L; Nadif, R; Neffen, H; Nekam, K; Nieto, A; Niggemann, B; Nogueira-Silva, L; Nogues, M; Nyembue, TD; Ohta, K; Okamoto, Y; Okubo, K; Olive-Elias, M; Ouedraogo, S; Paggiaro, P; Pali-Schöll, I; Palkonen, S; Panzner, P; Papi, A; Park, HS; Passalacqua, G; Pedersen, S; Pereira, AM; Pfaar, O; Picard, R; Pigearias, B; Pin, I; Plavec, D; Pohl, W; Popov, TA; Portejoie, F; Postma, D; Poulsen, LK; Price, D; Rabe, KF; Raciborski, F; Roberts, G; Robalo-Cordeiro, C; Rodenas, F; Rodriguez-Mañas, L; Rolland, C; Roman Rodriguez, M; Romano, A; Rosado-Pinto, J; Rosario, N; Rottem, M; Sanchez-Borges, M; Sastre-Dominguez, J; Scadding, GK; Scichilone, N; Schmid-Grendelmeier, P; Serrano, E; Shields, M; Siroux, V; Sisul, JC; Skrindo, I; Smit, HA; Solé, D; Sooronbaev, T; Spranger, O; Stelmach, R; Sterk, PJ; Strandberg, T; Sunyer, J; Thijs, C; Triggiani, M; Valenta, R; Valero, A; van Eerd, M; van Ganse, E; van Hague, M; Vandenplas, O; Varona, LL; Vellas, B; Vezzani, G; Vazankari, T; Viegi, G; Vontetsianos, T; Wagenmann, M; Walker, S; Wang, DY; Wahn, U; Werfel, T; Whalley, B; Williams, DM; Williams, S; Wilson, N; Wright, J; Yawn, BP; Yiallouros, PK; Yusuf, OM; Zaidi, A; Zar, HJ; Zernotti, ME; Zhang, L; Zhong, N; Zidarn, M
    The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.
    2016Artigo científico Acesso aberto Ver mais
  • ARIA 2019: An Integrated Care Pathway for Allergic Rhinitis in Portugal
    Publication . Fonseca, J; Taveira-Gomes, T; Pereira, AM; Branco-Ferreira, M; Carreiro-Martins, P; Alves-Correia, M; Correia de Sousa, J; Costa, E; Lourenço, O; Morais-Almeida, M; Morête, A; Regateiro, F; Todo Bom, A; Bachert, C; Pfaar, O; Wallace, D; Bedbrook, A; Czarlewski, W; Bousquet, J
    The Allergic Rhinitis and Its Impact on Asthma (ARIA) initiative started more than 20 years ago and has developed and disseminated evidence-based guidelines and projects in the field of allergic rhinitis. This initiative is currently focused on providing patient-centred guidelines that contribute to an integrated care pathway between the various levels of care and take advantage of digital solutions, and the introduction of integrated care pathways in clinical practice has been recommended. In this article we describe the adaptation for Portugal of the ARIA Integrated Care Pathways document. After a brief review of the epidemiology and impact of allergic rhinitis in Portugal and the activities carried out in Portugal within the ARIA initiative, we describe the broad knowledge base used for the development of recommendations for the pharmacological treatment of allergic rhinitis, and these recommendations are based on the GRADE methodology, real world evidence acquired by mobile technology (mHealth) and resulting from allergenic exposure chamber studies. What follows is a summary of integrated care pathways for allergen immunotherapy produced in 2019. Allergen immunotherapy is considered an example of precision medicine where the use of mHealth technologies will improve stratification for patient selection and response monitoring. These recommendations were considered as best practices of integrated patient-centred care supported by digital systems from Directorate General for Health and Food Safety of the European Union (DG Santé) and represent the ARIA Phase 4 Change Management strategy.
    2021-02-01Artigo científico Acesso aberto Ver mais
  • ARIA Digital Anamorphosis: Digital Transformation of Health and Care in Airway Diseases from Research to Practice
    Publication . Bousquet, J; Anto, JM; Bachert, C; Haahtela, T; Zuberbier, T; Czarlewski, W; Bedbrook, A; Bosnic-Anticevich, S; Walter Canonica, G; Cardona, V; Costa, E; Costa, DJ; Courbis, AL; Custovic, A; Cvetkosvki, B; D'Amato, G; da Silva, J; Dantas, C; Dokic, D; Dauvilliers, Y; De Feo, G; Cruz, AA; De Vries, G; Devillier, P; Di Capua, S; Dray, G; Dubakiene, R; Durham, SR; Dykewicz, M; Ebisawa, M; Gaga, M; El-Gamal, Y; Erhola, M; Heffler, E; Emuzyte, R; Farrell, J; Fauquert, JL; Fiocchi, A; Fink-Wagner, A; Fontaine, JF; Fuentes Perez, JM; Gemicioğlu, B; Gamkrelidze, A; Fokkens, WJ; Garcia-Aymerich, J; Gevaert, P; Gomez, RM; González Diaz, S; Gotua, M; Guldemond, NA; Guzmán, MA; Hajjam, J; Huerta Villalobos, YR; Humbert, M; Fonseca, JA; Iaccarino, G; Ierodiakonou, D; Iinuma, T; Jassem, E; Joos, G; Jung, K; Kaidashev, I; Kalayci, O; Kardas, P; Keil, T; Illario, M; Khaitov, M; Khaltaev, N; Kleine-Tebbe, J; Kouznetsov, R; Kull, I; La Grutta, S; Leonardini, L; Ljungberg, H; Lieberman, P; Lipworth, B; Ivancevich, JC; Lodrup Carlsen, K; Lopes-Pereira, C; Loureiro, C; Louis, R; Mair, A; Mahboub, B; Makris, M; Malva, J; Manning, P; Marshall, G; Jutel, M; Masjedi, M; Carreiro-Martins, P; Makela, M; Mathieu-Dupas, E; Maurer, M; De Manuel Keenoy, E; Melo-Gomes, E; Meltzer, E; Menditto, E; Mercier, J; Klimek, L; Micheli, Y; Miculinic, N; Mihaltan, F; Milenkovic, B; Mitsias, D; Moda, G; Mogica-Martinez, MD; Mohammad, Y; Montefort, S; Monti, R; Kuna, P; Morais-Almeida, M; Mösges, R; Münter, L; Muraro, A; Murray, R; Naclerio, R; Napoli, L; Namazova-Baranova, L; Neffen, H; Nekam, K; Kvedariene, V; Neou, A; Nordlund, B; Novellino, E; Nyembue, D; O'Hehir, R; Ohta, K; Okubo, K; Onorato, G; Orlando, V; Ouedraogo, S; Le, L; Palamarchuk, J; Pali-Schöll, I; Panzner, P; Park, H; Passalacqua, G; Pépin, JL; Paulino, E; Pawankar, R; Phillips, J; Picard, R; Larenas-Linnemann, DE; Pinnock, H; Plavec, D; Popov, T; Portejoie, F; Price, D; Prokopakis, E; Psarros, F; Pugin, B; Puggioni, F; Quinones-Delgado, P; Laune, D; Raciborski, F; Rajabian-Söderlund, R; Regateiro, F; Reitsma, S; Rivero-Yeverino, D; Roberts, G; Roche, N; Rodriguez-Zagal, E; Rolland, C; Roller-Wirnsberger, R; Lourenço, OM; Rosario, N; Romano, A; Rottem, M; Ryan, D; Salimäki, J; Sanchez-Borges, M; Sastre, J; Scadding, G; Scheire, S; Schmid-Grendelmeier, P; Melén, Erik; Schünemann, H; Sarquis Serpa, F; Shamji, M; Sisul, JC; Sofiev, M; Solé, D; Somekh, D; Sooronbaev, T; Sova, M; Spertini, F; Mullol, J; Spranger, O; Stellato, C; Stelmach, R; Thibaudon, M; To, T; Toumi, M; Usmani, O; Valero, A; Valenta, R; Valentin-Rostan, M; Niedoszytko, M; Pereira, M; van der Kleij, R; Van Eerd, M; Vandenplas, O; Vasankari, T; Vaz Carneiro, A; Vezzani, G; Viart, F; Viegi, G; Wallace, D; Odemyr, M; Wagenmann, M; Wang, Y; Waserman, S; Wickman, M; Williams, D; Wong, G; Wroczynski, P; Yiallouros, P; Yusuf, O; Zar, HJ; Okamoto, Y; Zeng, S; Zernotti, ME; Zhang, L; Shan Zhong, N; Papadopoulos, NG; Patella, V; Pfaar, O; Pham-Thi, N; Rolland, C; Samolinski, B; Sheikh, A; Sofiev, M; Suppli Ulrik, C; Todo-Bom, A; Tomazic, PV; Toppila-Salmi, S; Tsiligianni, I; Valiulis, A; Valovirta, E; Ventura, MT; Walker, S; Williams, S; Yorgancioglu, A; Agache, I; Akdis, CA; Almeida, R; Ansotegui, IJ; Annesi-Maesano, I; Arnavielhe, S; Basagaña, X; D Bateman, E; Bédard, A; Bedolla-Barajas, M; Becker, S; Bennoor, KS; Benveniste, S; Bergmann, KC; Bewick, M; Bialek, S; E Billo, N; Bindslev-Jensen, C; Bjermer, L; Blain, H; Bonini, M; Bonniaud, P; Bosse, I; Bouchard, J; Boulet, LP; Bourret, R; Boussery, K; Braido, F; Briedis, V; Briggs, A; Brightling, CE; Brozek, J; Brusselle, G; Brussino, L; Buhl, R; Buonaiuto, R; Calderon, MA; Camargos, P; Camuzat, T; Caraballo, L; Carriazo, AM; Carr, W; Cartier, C; Casale, T; Cecchi, L; Cepeda Sarabia, AM; H Chavannes, N; Chkhartishvili, E; Chu, DK; Cingi, C; Correia de Sousa, J
    Digital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis. It strengthens the ARIA change management strategy in the prevention and management of airway disease. The MASK strategy is based on validated digital tools. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for practical steps of digital enhancement of care are proposed.
    2021Artigo científico Acesso aberto Ver mais
  • ARIA-EAACI Care Pathways for Allergen Immunotherapy in Respiratory Allergy
    Publication . Bousquet, J; Pfaar, O; Agache, I; Bedbrook, A; Akdis, CA; Canonica, GW; Chivato, T; Al-Ahmad, M; Abdul Latiff, AH; Ansotegui, IJ; Bachert, C; Baharuddin, A; Bergmann, KC; Bindslev-Jensen, C; Bjermer, L; Bonini, M; Bosnic-Anticevich, S; Bosse, I; Brough, HA; Brussino, L; Calderon, MA; Caraballo, L; Cardona, V; Carreiro-Martins, P; Casale, T; Cecchi, L; Cepeda Sarabia, AM; Chkhartishvili, E; Chu, DK; Cirule, I; Cruz, AA; Czarlewski, W; Del Giacco, S; Demoly, P; Devillier, P; Dokic, D; Durham, SL; Ebisawa, M; El-Gamal, Y; Emuzyte, R; Gamkrelidze, A; Fauquert, JL; Fiocchi, A; Fokkens, WJ; Fonseca, JA; Fontaine, JF; Gawlik, R; Gelincik, A; Gemicioglu, B; Gereda, JE; Gerth van Wijk, R; Gomez, RM; Gotua, M; Grisle, I; Guzmán, MA; Haahtela, T; Halken, S; Heffler, E; Hoffmann-Sommergruber, K; Hossny, E; Hrubiško, M; Irani, C; Ivancevich, JC; Ispayeva, Z; Julge, K; Kaidashev, I; Kalayci, O; Khaitov, M; Klimek, L; Knol, E; Kowalski, ML; Kraxner, H; Kull, I; Kuna, P; Kvedariene, V; Kritikos, V; Lauerma, A; Lau, S; Laune, D; Levin, M; Larenas-Linnemann, DE; Lodrup Carlsen, KC; Lombardi, C; Lourenço, OM; Mahboub, B; Malling, HJ; Manning, P; Marshall, GD; Melén, E; Meltzer, EO; Miculinic, N; Milenkovic, B; Moin, M; Montefort, S; Morais-Almeida, M; Mortz, CG; Mösges, R; Mullol, J; Namazova Baranova, L; Neffen, H; Nekam, K; Niedoszytko, M; Odemyr, M; O'Hehir, RE; Ollert, M; O'Mahony, L; Ohta, K; Okamoto, Y; Okubo, K; Pajno, GB; Palomares, O; Palkonen, S; Panzner, P; G Papadopoulos, N; Park, H; Passalacqua, G; Patella, V; Pawankar, R; Pham-Thi, N; Plavec, D; Popov, TA; Recto, M; Regateiro, FS; Riggioni, C; Roberts, G; Rodriguez-Gonzales, M; Rosario, N; Rottem, M; Rouadi, PW; Ryan, D; Samolinski, B; Sanchez-Borges, M; Serpa, FS; Sastre, J; Scadding, G; Shamji, M; Schmid-Grendelmeier, P; Schünemann, H; Sheikh, A; Scichilone, N; Sisul, JC; Sofiev, M; Solé, D; Sooronbaev, T; Soto-Martinez, M; Soto-Quiros, M; Sova, M; Schwarze, J; Skypala, I; Suppli-Ulrik, C; Taborda-Barata, L; Todo-Bom, A; Torres, MJ; Valentin-Rostan, M; Tomazic, PV; Valero, A; Toppila-Salmi, S; Tsiligianni, I; Untersmayr, E; Urrutia-Pereira, M; Valiulis, A; Valovirta, E; Vandenplas, O; Ventura, MT; Vichyanond, P; Wagenmann, M; Wallace, D; Walusiak-Skorupa, J; Wang, DY; Waserman, S; Wong, GW; Yorgancioglu, A; Yusuf, OM; Zernotti, M; Zhang, L; Zidarn, M; Zuberbier, T; Jutel, M
    2021-06Artigo científico Acesso aberto Ver mais
  • Behavioural Patterns in Allergic Rhinitis Medication in Europe: A Study Using MASK‐Air ® Real‐World Data
    Publication . Sousa‐Pinto, B; Sá‐Sousa, A; Vieira, RJ; Amaral, R; Klimek, L; Czarlewski, W; Antó, JM; Pfaar, O; Bedbrook, A; Kvedariene, V; Ventura, MT; Ansotegui, IJ; Bergmann, KC; Brussino, L; Canonica, GW; Cardona, V; Carreiro‐Martins, P; Casale, T; Cecchi, L; Chivato, T; Chu, DK; Cingi, C; Costa, EM; Cruz, AA; De Feo, G; Devillier, P; Fokkens, WJ; Gaga, M; Gemicioğlu, B; Haahtela, T; Ivancevich, JC; Ispayeva, Z; Jutel, M; Kuna, P; Kaidashev, I; Kraxner, H; Larenas‐Linnemann, DE; Laune, D; Lipworth, B; Louis, R; Makris, M; Monti, R; Morais‐Almeida, M; Mösges, R; Mullol, J; Odemyr, M; Okamoto, Y; Papadopoulos, NG; Patella, V; Pham‐Thi, N; Regateiro, FS; Reitsma, S; Rouadi, PW; Samolinski, B; Sova, M; Todo‐Bom, A; Taborda‐Barata, L; Tomazic, PV; Toppila‐Salmi, S; Sastre, J; Tsiligianni, I; Valiulis, A; Vandenplas, O; Wallace, D; Waserman, S; Yorgancioglu, A; Zidarn, M; Zuberbier, T; Fonseca, JA; Bousquet, J
    Background: Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. Methods: We analysed 2015-2020 MASK-air® European data. We compared days under no medication, monotherapy and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms ('VAS Global Symptoms') and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within 1 year. Results: We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median 'VAS Global Symptoms' was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p < .001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral H1 -antihistamines were the most common medication in single and co-medication. Each patient reported using an annual average of 2.7 drugs, with 80% reporting two or more. Conclusions: Allergic rhinitis medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR) and that co-medication use is driven by symptom severity.
    2022Artigo científico Acesso aberto Ver mais
  • Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference
    Publication . Sousa‐Pinto, B; Schünemann, HJ; Sá‐Sousa, A; Vieira, RJ; Amaral, R; Anto, JM; Klimek, L; Czarlewski, W; Mullol, J; Pfaar, O; Bedbrook, A; Brussino, L; Kvedariene, V; Larenas‐Linnemann, D; Okamoto, Y; Ventura, MT; Agache, I; Ansotegui, IJ; Bergmann, KC; Bosnic‐Anticevich, S; Brozek, J; Canonica, GW; Cardona, V; Carreiro‐Martins, P; Casale, T; Cecchi, L; Chivato, T; Chu, DK; Cingi, C; Costa, EM; Cruz, AA; Del Giacco, S; Devillier, P; Eklund, P; Fokkens, WJ; Gemicioglu, B; Haahtela, T; Ivancevich, JC; Ispayeva, Z; Jutel, M; Kuna, P; Kaidashev, I; Khaitov, M; Kraxner, H; Laune, D; Lipworth, B; Louis, R; Makris, M; Monti, R; Morais‐Almeida, M; Mösges, R; Niedoszytko, M; Papadopoulos, NG; Patella, V; Pham‐Thi, N; Regateiro, FS; Reitsma, S; Rouadi, PW; Samolinski, B; Sheikh, A; Sova, M; Todo‐Bom, A; Taborda‐Barata, L; Toppila‐Salmi, S; Sastre, J; Tsiligianni, I; Valiulis, A; Vandenplas, O; Wallace, D; Waserman, S; Yorgancioglu, A; Zidarn, M; Zuberbier, T; Fonseca, JA.; Bousquet, J
    Background: Different treatments exist for allergic rhinitis (AR), including pharmacotherapy and allergen immunotherapy (AIT), but they have not been compared using direct patient data (i.e., "real-world data"). We aimed to compare AR pharmacological treatments on (i) daily symptoms, (ii) frequency of use in co-medication, (iii) visual analogue scales (VASs) on allergy symptom control considering the minimal important difference (MID) and (iv) the effect of AIT. Methods: We assessed the MASK-air® app data (May 2015-December 2020) by users self-reporting AR (16-90 years). We compared eight AR medication schemes on reported VAS of allergy symptoms, clustering data by the patient and controlling for confounding factors. We compared (i) allergy symptoms between patients with and without AIT and (ii) different drug classes used in co-medication. Results: We analysed 269,837 days from 10,860 users. Most days (52.7%) involved medication use. Median VAS levels were significantly higher in co-medication than in monotherapy (including the fixed combination azelastine-fluticasone) schemes. In adjusted models, azelastine-fluticasone was associated with lower average VAS global allergy symptoms than all other medication schemes, while the contrary was observed for oral corticosteroids. AIT was associated with a decrease in allergy symptoms in some medication schemes. A difference larger than the MID compared to no treatment was observed for oral steroids. Azelastine-fluticasone was the drug class with the lowest chance of being used in co-medication (adjusted OR = 0.75; 95% CI = 0.71-0.80). Conclusion: Median VAS levels were higher in co-medication than in monotherapy. Patients with more severe symptoms report a higher treatment, which is currently not reflected in guidelines.
    2022Artigo científico Acesso aberto Ver mais
  • Consistent Trajectories of Rhinitis Control and Treatment in 16,177 Weeks: The MASK‐air® Longitudinal Study
    Publication . Sousa‐Pinto, B; Schünemann, HJ; Sá‐Sousa, A; Vieira, RJ; Amaral, R; Anto, JM; Klimek, L; Czarlewski, W; Mullol, J; Pfaar, O; Bedbrook, A; Brussino, L; Kvedariene, V; Larenas‐Linnemann, DE; Okamoto, Y; Ventura, MT; Agache, I; Ansotegui, IJ; Bergmann, KC; Bosnic‐Anticevich, S; Canonica, GW; Cardona, V; Carreiro‐Martins, P; Casale, T; Cecchi, L; Chivato, T; Chu, DK; Cingi, C; Costa, EM; Cruz, AA; Del Giacco, S; Devillier, P; Eklund, P; Fokkens, WJ; Gemicioglu, B; Haahtela, T; Ivancevich, JC; Ispayeva, Z; Jutel, M; Kuna, P; Kaidashev, I; Khaitov, M; Kraxner, H; Laune, D; Lipworth, B; Louis, R; Makris, M; Monti, R; Morais‐Almeida, M; Mösges, R; Niedoszytko, M; Papadopoulos, NG; Patella, V; Pham‐Thi, N; Regateiro, FS; Reitsma, S; Rouadi, PW; Samolinski, B; Sheikh, A; Sova, M; Todo‐Bom, A; Taborda‐Barata, L; Toppila‐Salmi, S; Sastre, J; Tsiligianni, I; Valiulis, A; Vandenplas, O; Wallace, D; Waserman, S; Yorgancioglu, A; Zidarn, M; Zuberbier, T; Fonseca, JA; Bousquet, J
    Introduction: Data from mHealth apps can provide valuable information on rhinitis control and treatment patterns. However, in MASK-air®, these data have only been analyzed cross-sectionally, without considering the changes of symptoms over time. We analyzed data from MASK-air® longitudinally, clustering weeks according to reported rhinitis symptoms. Methods: We analyzed MASK-air® data, assessing the weeks for which patients had answered a rhinitis daily questionnaire on all 7 days. We firstly used k-means clustering algorithms for longitudinal data to define clusters of weeks according to the trajectories of reported daily rhinitis symptoms. Clustering was applied separately for weeks when medication was reported or not. We compared obtained clusters on symptoms and rhinitis medication patterns. We then used the latent class mixture model to assess the robustness of results. Results: We analyzed 113,239 days (16,177 complete weeks) from 2590 patients (mean age ± SD = 39.1 ± 13.7 years). The first clustering algorithm identified ten clusters among weeks with medication use: seven with low variability in rhinitis control during the week and three with highly-variable control. Clusters with poorly-controlled rhinitis displayed a higher frequency of rhinitis co-medication, a more frequent change of medication schemes and more pronounced seasonal patterns. Six clusters were identified in weeks when no rhinitis medication was used, displaying similar control patterns. The second clustering method provided similar results. Moreover, patients displayed consistent levels of rhinitis control, reporting several weeks with similar levels of control. Conclusions: We identified 16 patterns of weekly rhinitis control. Co-medication and medication change schemes were common in uncontrolled weeks, reinforcing the hypothesis that patients treat themselves according to their symptoms.
    2023Artigo científico Acesso aberto Ver mais
  • COVID-19 Pandemic: Practical Considerations on the Organization of an Allergy Clinic-An EAACI/ARIA Position Paper
    Publication . Pfaar, O; Klimek, L; Jutel, M; Akdis, CA; Bousquet, J; Breiteneder, H; Chinthrajah, S; Diamant, Z; Eiwegger, T; Fokkens, WJ; Fritsch, HW; Nadeau, KC; O'Hehir, RE; O'Mahony, L; Rief, W; Sampath, V; Schedlowski, M; Torres, MJ; Traidl-Hoffmann, C; Wang, Y; Zhang, L; Bonini, M; Brehler, R; Brough, HA; Chivato, T; Del Giacco, SR; Dramburg, S; Gawlik, R; Gelincik, A; Hoffmann-Sommergruber, K; Hox, V; Knol, EF; Lauerma, A; Matricardi, PM; Mortz, CG; Ollert, M; Palomares, O; Riggioni, C; Schwarze, J; Skypala, I; Untersmayr, E; Walusiak-Skorupa, J; Ansotegui, IJ; Bachert, C; Bedbrook, A; Bosnic-Anticevich, S; Brussino, L; Canonica, GW; Cardona, V; Carreiro-Martins, P; Cruz, AA; Czarlewski, W; Fonseca, JA; Gotua, M; Haahtela, T; Ivancevich, JC; Kuna, P; Kvedariene, V; Larenas-Linnemann, DE; Abdul Latiff, AH; Mäkelä, M; Morais-Almeida, M; Mullol, J; Naclerio, R; Ohta, K; Okamoto, Y; Onorato, GL; Papadopoulos, NG; Patella, V; Regateiro, FS; Samoliński, B; Suppli Ulrik, C; Toppila-Salmi, S; Valiulis, A; Ventura, MT; Yorgancioglu, A; Zuberbier, T; Agache, I
    The coronavirus disease 2019 (COVID-19) has evolved into a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Allergists and other healthcare providers (HCPs) in the field of allergies and associated airway diseases are on the front line, taking care of patients potentially infected with SARS-CoV-2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics.
    2021Artigo científico Acesso aberto Ver mais
  • Digitally‐Enabled, Patient‐Centred Care in Rhinitis and Asthma Multimorbidity: The ARIA‐MASK‐air ® Approach
    Publication . Bousquet, J; Anto, JM; Sousa‐Pinto, B; Czarlewski, W; Bedbrook, A; Haahtela, T; Klimek, L; Pfaar, O; Kuna, P; Kupczyk, M; Regateiro, FS; Samolinski, B; Valiulis, A; Yorgancioglu, A; Arnavielhe, S; Basagaña, X; Bergmann, KC; Bosnic‐Anticevich, S; Brussino, L; Canonica, GW; Cardona, V; Cecchi, L; Chaves‐Loureiro, C; Costa, E; Cruz, AA; Gemicioglu, B; Fokkens, W; Ivancevich, JC; Kraxner, H; Kvedariene, V; Larenas‐Linnemann, DE; Laune, D; Louis, R; Makris, M; Maurer, M; Melén, E; Micheli, Y; Morais‐Almeida, M; Mullol, J; Niedoszytko, M; Okamoto, Y; Papadopoulos, NG; Patella, V; Pham‐Thi, N; Rouadi, PW; Sastre, J; Scichilone, N; Sheikh, A; Sofiev, M; Taborda‐Barata, L; Toppila‐Salmi, S; Tsiligianni, I; Valovirta, E; Ventura, MT; Vieira, RJ; Zidarn, M; Amaral, R; Ansotegui, IJ; Bédard, A; Benveniste, S; Bewick, M; Bindslev‐Jensen, C; Blain, H; Bonini, M; Bourret, R; Braido, F; Carreiro‐Martins, P; Charpin, D; Cherrez‐Ojeda, I; Chivato, T; Chu, DK; Cingi, C; Del Giacco, S; de Blay, F; Devillier, P; De Vries, G; Doulaptsi, M; Doyen, V; Dray, G; Fontaine, JF; Gomez, RM; Hagemann, J; Heffler, E; Hofmann, M; Jassem, E; Jutel, M; Keil, T; Kritikos, V; Kull, I; Kulus, M; Lourenço, O; Mathieu‐Dupas, E; Menditto, E; Mösges, R; Murray, R; Nadif, R; Neffen, H; Nicola, S; O’Hehir, R; Olze, H; Palamarchuk, Y; Pépin, JL; Pétré, B; Picard, R; Pitsios, C; Puggioni, F; Quirce, S; Raciborski, F; Reitsma, S; Roche, N; Rodriguez‐Gonzalez, M; Romantowski, J; Sá‐Sousa, A; Serpa, FS; Savouré, M; Shamji, MH; Sova, M; Sperl, A; Stellato, C; Todo‐Bom, A; Tomazic, PV; Vandenplas, O; Van Eerd, M; Vasankari, T; Viart, F; Waserman, S; Fonseca, JA; Zuberbier, T
    MASK-air® , a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air® is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co-operation and Development). MASK-air® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK-air® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as-needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom-medication score (ARIA-EAACI-CSMS) has been validated for clinical practice and trials. The implications of the novel MASK-air® results should lead to change management in rhinitis and asthma.
    2023Artigo científico Acesso aberto Ver mais